ERBB2 and neoplasm: In the case of DESTINY-PanTumour-02, an impressive overall response rate (ORR) of 57.5% was observed in a cohort of HER2-expressing endometrial cancers (40 patients), with ORR reaching 84.6% in IHC 3+ tumours [5].